Immune checkpoint inhibitors (ICIs) are effective for many cancers but can be limited by inflammatory toxicities. Little is known about how ICIs affect the reproductive system. New research in animal models with and without tumours demonstrates that ovarian reserves are depleted in mice treated with ICIs, which may influence fertility.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H. & Sharpe, A. H. Trends Immunol. 40, 511–523 (2019).
Dougan, M., Luoma, A. M., Dougan, S. K. & Wucherpfennig, K. W. Cell 184, 1575–1588 (2021).
Johnson, D. B., Balko, J. M. & Compton, M. L. et al. N. Engl. J. Med. 375, 1749–1755 (2016).
Wang, D. Y. et al. JAMA Oncol. 4, 1721–1728 (2018).
Winship, A. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00413-x (2022).
Tawbi, H. A. et al. N. Engl. J. Med. 386, 24–34 (2022).
Luoma, A. M. et al. Cell 182, 655–671.e22 (2020).
Sasson, S. C. et al. Gastroenterology 161, 1229–1244.e9 (2021).
Cercek, A. et al. N. Engl. J. Med. 386, 2363–2376 (2022).
Xu, P. C. et al. J. Endocrinol. 252, 15–30 (2021).
NCCN Guidelines https://go.nature.com/3aYuv8a (National Comprehensive Cancer Network, accessed 6 June 2022).
Duma, N. & Lambertini, M. Oncologist 25, 277–278 (2020).
Alesi, L. R., Winship, A. L. & Hutt, K. J. Curr. Opin. Endocr. Metab. Res. 18, 15–28 (2021).
Mittra, A. et al. Oncologist 26, e1883–e1886 (2021).
Garutti, M., Lambertini, M. & Puglisi, F. ESMO Open 6, 100291 (2021). erratum 6, 100276 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.D. has research funding from Novartis and Eli Lilly and Company; has received consulting fees from Tillotts Pharma, ORIC Pharmaceuticals, Partner Therapeutics, SQZ Biotech, AzurRx, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Aditum and Moderna; and is a member of the scientific advisory board for Neoleukin Therapeutics. S.A.R. declares no competing interests.
Rights and permissions
About this article
Cite this article
Roberts, S.A., Dougan, M. Checking ovarian reserves after checkpoint blockade. Nat Cancer 3, 907–908 (2022). https://doi.org/10.1038/s43018-022-00422-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00422-w
This article is cited by
-
Effects of Cetrorelix on Ovary and Endometrium Prior to Anti-PD-L1 Antibody in Murine Model
Tissue Engineering and Regenerative Medicine (2023)